Professor and Vice Chairman of Neurosurgery
University at Buffalo
Buffalo, New York, United States
Dr. Adnan H. Siddiqui, is Professor and Vice Chairman in the Department of Neurosurgery (UBNS) at the State University of New York at Buffalo’s Jacobs School of Medicine and Biomedical Sciences. He also serves as the Chief Executive Officer and Chief Medical Officer at the Jacobs Institute (JI) which is focused on entrepreneurship, development and education opportunities with partners in the medical technology industry including strategics, startups and individual inventors to advance the care of patients with vascular diseases.
Dr. Siddiqui has special interest and expertise in the performance of complementary microsurgical, radiosurgical and endovascular techniques for the comprehensive management of cerebrovascular conditions. This spectrum of disease includes aneurysms and arteriovenous malformations, as well as dural, cavernous and spinal fistulae. He has special interests in endovascular management of acute ischemic stroke, as well as endovascular and microsurgical management of extracranial and intracranial vascular occlusive disease. Other clinical interests include endovascular management of intractable epistaxis, facial vascular malformations, head, neck, and brain tumor embolization and microsurgical resection of skull base tumors.
Dr. Siddiqui has over 450 peer reviewed publications, more than 50 chapters, almost 70,000 citations and an H index of 72. He is particularly proud of representing Buffalo and the US at most major cerebrovascular conferences around the world with over 200 international presentations to date. He has designed, conducted and lead multiple major national and international clinical trials and currently serves as National and International PI for multiple major funded multi-site trials. These efforts have significantly contributed to the success of the department, which was ranked 7th in academic impact in North America by the Journal of Neurosurgery.
Sunday, April 23, 2023
1:35pm – 2:05pm PST
Disclosure(s): .Rist Neurovascular, Inc.: Stock Shareholder (excluding mutual funds) (Terminated, October 1, 2020); Adona Medical, Inc: Stock Shareholder (excluding mutual funds) (Ongoing); Amnis Therapeutics,: Consultant (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); Apellis Pharmaceuticals, Inc.: Consultant (Ongoing); Bend IT Technologies, Ltd.: Stock Shareholder (excluding mutual funds) (Ongoing); BlinkTBI, Inc: Stock Shareholder (excluding mutual funds) (Ongoing); Borvo Medical, Inc.: Stock Shareholder (excluding mutual funds) (Ongoing); Boston Scientific: Consultant (Ongoing); Canon Medical Systems USA, Inc.: Consultant (Ongoing); Cardinal Health 200, LLC: Consultant (Ongoing); Cerebrotech Medical Systems, Inc.: Consultant (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); Cerenovus: Consultant (Ongoing); Cerevatech Medical, Inc.: Consultant (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); Cognition Medical: Stock Shareholder (excluding mutual funds) (Ongoing); Collavidence, Inc.: Stock Shareholder (excluding mutual funds) (Ongoing); Cordis Corporation: Consultant (Ongoing); Corindus, Inc.: Consultant (Ongoing); CVAID Ltd.: Stock Shareholder (excluding mutual funds) (Ongoing); E8, Inc.: Stock Shareholder (excluding mutual funds) (Ongoing); Endostream Medical, Ltd: Consultant (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); Galaxy Therapeutics, Inc.: Stock Shareholder (excluding mutual funds) (Ongoing); Imperative Care, Inc.: Advisor (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); InspireMD, Ltd.: Consultant (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); Instylla, Inc.: Stock Shareholder (excluding mutual funds) (Ongoing); Integra Lifesciences, Corp: Consultant (Ongoing); IRRAS AB: Consultant (Ongoing); Launch NY, Inc.: Stock Shareholder (excluding mutual funds) (Ongoing); Medtronic: Consultant (Ongoing); Microvention: Consultant (Ongoing); Minnetronix Neuro, Inc.: Consultant (Ongoing); Neurolutions: Stock Shareholder (excluding mutual funds) (Ongoing); NeuroRadial Technologies, Inc.: Stock Shareholder (excluding mutual funds) (Ongoing); Neurovascular Diagnostics, Inc.: Stock Shareholder (excluding mutual funds) (Ongoing); Peijia Medical: Consultant (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); Penumbra: Consultant (Ongoing); Perflow Medical, Ltd.: Stock Shareholder (excluding mutual funds) (Ongoing); Piraeus Medical, Inc.: Consultant (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); Q’Apel Medical, Inc.: Consultant (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); QAS.ai, Inc.: Stock Shareholder (excluding mutual funds) (Ongoing); Radical Catheter Technologies, Inc.: Stock Shareholder (excluding mutual funds) (Ongoing); Rapid Medical: Consultant (Ongoing); Sense Diagnostics, Inc.: Stock Shareholder (excluding mutual funds) (Ongoing); Serenity Medical, Inc.: Stock Shareholder (excluding mutual funds) (Ongoing); Silk Road Medical: Consultant (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); Sim & Cure: Stock Shareholder (excluding mutual funds) (Ongoing); SongBird Therapy: Stock Shareholder (excluding mutual funds) (Ongoing); Spinnaker Medical, Inc.: Stock Shareholder (excluding mutual funds) (Ongoing); StimMed, LLC: Consultant (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); Stryker Neurovascular: Consultant (Ongoing); Synchron, Inc.: Stock Shareholder (excluding mutual funds) (Ongoing); Three Rivers Medical, Inc: Consultant (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); Truvic Medical, Inc.: Stock Shareholder (excluding mutual funds) (Ongoing); Tulavi Therapeutics, Inc.: Stock Shareholder (excluding mutual funds) (Ongoing); VasSol: Consultant (Ongoing); Vastrax, LLC: Stock Shareholder (excluding mutual funds) (Ongoing); VICIS, Inc.: Stock Shareholder (excluding mutual funds) (Ongoing); Viseon, Inc: Stock Shareholder (excluding mutual funds) (Ongoing); Viz.ai, Inc.: Consultant (Ongoing); Whisper Medical, Inc.: Stock Shareholder (excluding mutual funds) (Ongoing)